Specialty Pharmacy

Novartis’ siponimod (Mayzent) is approved for adults with active secondary progressive multiple sclerosis, clinically isolated syndrome, and relapsing-remitting disease.

Program uses archived samples from patients with known treatment outcomes to accelerate research in predicting therapeutic responses for future patients with cancer.

Managed Health Care Associates’ Annual Business Summit covers wide range of topics, including insights on managing cost and improving operational efficiencies.

Top news of the day from across the health care industry.

Study finds chronic hepatitis C virus infection should not delay the initiation of an urgent cancer therapy.

Preventive drugs are frequently continued in patients with cancer near end of life despite limited clinical benefit.

Study finds older patients administered combined immunosuppression experienced similar remission of Crohn disease as those aged under 60 years.

Top news of the day from across the health care industry.

Achievable steps could be taken to reach the World Health Organization goal of eliminating hepatitis B and C virus infections as public health threats by 2030.

Study is the first and largest of its kind to examine mortality associated with beta interferons, the first drugs to be approved for the treatment of relapsing-onset multiple sclerosis.

Top news of the day from across the health care industry.

Chris Kepinski, PharmD, sat down with Specialty Pharmacy Times at the National Community Oncology Dispensing Association conference in Denver, Colorado to discuss how treatment support kits act a vital resource for patients throughout their treatment.

A novel vaccine to prevent hepatitis C infection has been tested in Baltimore and at two other sites in the United States.

Interim phase 3 trial results showed an increased risk of death for patients receiving venetoclax for multiple myeloma.

Although there have been links between esophageal cancer and drinking hot tea, this was the first study to examine a specific temperature.

A phase 3 study compared overall survival and cardiac safety between biosimilar trastuzumab (Ontruzant) and the reference medicine.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care industry.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Patients with multiple sclerosis who consumed 2 cans of soda per day were 5 times more likely to experience severe disability.

Solriamfetol (Sunosi, Jazz Pharmaceuticals) is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved for this indication.

When combined, treatment with metformin and heme suppressed tumor growth in mice.

A pilot study suggests compounds found in coffee may slow the growth of prostate cancer.

Top news of the day from across the health care industry.

Officials with the FDA have approved brexanolone (Zulresso, Sage Therapeutics) injection for intravenous use for the treatment of postpartum depression in adult women.

Higher body mass index at beginning of menstruation linked to greater risk of developing multiple sclerosis.

Lawsuit alleges that patients paid artificially high prices for brand-name Humira, and that they were deprived of the benefits of early, robust competition from biosimilars as a result of wrongful conduct.

Operating a specialty pharmacy is a great benefit to health systems that adopt it early, while those who wait are going to face higher risks and have a lower probability of success.